Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Enters Mutation Discovery Partnership with Novartis

NEW YORK, Dec. 2 (GenomeWeb News) - Transgenomic today said that it has entered into "several specific agreements" with Novartis Pharmaceuticals to provide mutation discovery services to support translational research programs in oncology.

Transgenomic said that the goal of the collaboration is to support biomarker discovery efforts in clinical trials by identifying genetic mutations that correlate with patients' response or responses to cancer therapeutics. Transgenomic said it has already performed proof-of-principle work and begun to deliver data for the projects.

The companies have several specific project agreements, according to Transgenomic, including a clinical assay/protocol development project.

"Novartis Oncology is dedicated to incorporating knowledge of genomic changes associated with cancer into the drug development process," said Kenneth Culver, global head of translational medicine at Novartis Oncology. He added that the company is using Transgenomic's WAVE technology to detect low-abundance mutations in clinical specimens, and to scan for mutations "rather than develop specific assays for each potential mutation."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more